Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
2016
BackgroundHigher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides. MethodsWe sequenced the exons of ANGPTL4 in samples obtain from 42,930 participants of predominantly European ancestry in the DiscovEHR human genetics study. We performed tests of association between lipid levels and the missense E40K variant (which has been associated with reduced plasma triglyceride levels) and other inactivating mutations. We then tested for associations between coronary artery disease and the E40K variant and other inactivating mutations in 10,552 participants with coronary artery disease and 29,223 controls. We also tested the effect of a human monoclonal antibody against ANGPTL4 on lipid levels in mice and monkeys. ResultsWe identified 1661 heterozygotes and 17 homozygotes for the E40K variant and 75 participa...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
40
References
292
Citations
NaN
KQI